Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease
Article in Frontiers in Genetics (April 2024)
The most recent citing publications are shown below. View all 61 publications that cite this research output on Dimensions.
Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada
Article in Health Policy (March 2024)
Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing
Article in Kidney International (July 2023)